leadf
logo-loader
viewMaxCyte Inc

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a natural progression based on promising preliminary data from the study which was presented at the virtual meeting of the American Society of Clinical Oncology (ASCO) in May.

 

Read MaxCyte: Expanded prospects for CARMA

Quick facts: MaxCyte Inc

Price: 370 GBX

AIM:MXCT
Market: AIM
Market Cap: £285.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

MaxCyte report 'extraordinary first half' with revenue 30% higher than same...

Maxcyte Inc's (LON:MXCT) Doug Doerfler talks to Proactive London about their full-year revenues which are on track to be 'slightly above' current market expectations. Doerfler discusses what he describes as an 'extraordinary first half' with half year revenue 30% higher than the same period...

6 hours, 14 minutes ago

2 min read